ArticleBMC medical imaging2026
Revolution APEX CT: preliminary assessment of its application value in pancreatic cancer T staging.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo evaluate the diagnostic value of Revolution APEX energy spectrum CT imaging and quantitative parameters in T staging of pancreatic cancer (PCa).
methodsEnergy spectrum CT of 105 patients diagnosed with PCa confirmed by pathologic biopsy and 72 controls from June 2022 to January 2025 were retrospectively obtained. Patients were pathologically confirmed as PCa (15 patients with T1 stage, 23 patients with T2 stage, 46 patients with T3 stage, and 21 patients with T4 stage). Energy spectrum CT captured 40 keV, 70 keV, and 120 kVp-like images (Equivalent to conventional CT images at approximately 120 kVp), which were analyzed for contrast-to-noise ratio (CNR), noise, signal-to-noise ratio (SNR), and subjective scores. Normalized iodine concentration (NICtumor), energy spectrum slope (k), attenuation coefficient, and normalized CT value were quantitatively assessed, and the diagnostic efficacy was analyzed by ROC curve and area under the curve (AUC).
resultsThe control group and each T-staging subgroup did not differ significantly in age, gender, and BMI, although tumor diameter significantly increased with advancing T-staging (P < 0.001). The 70 keV images outperformed the control group in noise control, SNR, and subjective scores, despite having a significantly lower CNR in the tumor group (P < 0.001). Energy spectrum parameters changed significantly with T staging, including NICtumor (T1: 38.7% to T4: 64.0%), k value (T1: 1.3 to T4: 2.6 HU/keV), and attenuation coefficient (T1: 0.9 to T4: 1.6 HU/keV) (all P < 0.001). The AUC for NICtumor and k combined was 93.40% (sensitivity: 94.03%, specificity: 81.50%) in differentiating early from late stages, significantly surpassing the performance of a single parameter (P < 0.001).
conclusionThis preliminary study suggests that the 70 keV images from Revolution APEX spectral CT, combined with a multiparametric model based on standardized iodine concentration and spectral slope, demonstrate potential value in distinguishing pancreatic cancer T staging. This approach may provide additional quantitative radiographic reference information for preoperative assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.